Real-World Evidence: Optimizing Patient Selection for CAR T-Cell Therapy in Large B-Cell Lymphoma

This OncLive® Insights program explores how real-world evidence (RWE) is shaping the use of CAR T-cell therapy in relapsed or refractory large B-cell lymphoma (LBCL). Dr. Megan Melody, Dr. Miguel-Angel Perales, and Dr. Nirav Shah discuss the evolving role of the three FDA-approved CD19-directed CAR T-cell therapies, including their positioning across the second- and later-line settings and how RWE complements pivotal clinical trial data. The panel examines how clinicians can use real-world data to assess CAR T-cell candidacy beyond traditional trial eligibility criteria, considering age, comorbidities, performance status, disease burden, geriatric vulnerabilities, and practical support systems. The discussion also addresses timely referral, bridging therapy, site-of-care considerations, outpatient delivery, and post-infusion logistics. Throughout the program, the experts highlight how RWE can support individualized treatment decisions and help clinicians identify the right patient for CAR T-cell therapy at the right time.